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This case-controlled study explored the relationship between bone mineral density (BMD) and long-term treatment with
antiepileptic drugs (AEDs) in older adults with epilepsy. Seventy-eight patients (47 post-menopausal females, 31 males, aged
47–76 years) with epilepsy participated in the study. Each had only ever received treatment with either enzyme-inducing
(n = 52) or non-inducing (n = 26) AEDs. Individuals were matched for age, sex, height and weight with a drug-naive control.
All patients underwent bone densitometry at the lumbar spine and femoral neck and had blood sampling and urine collected for
a range of bone markers. Male patients had lower BMD than controls at the lumbar spine (P < 0.01) and neck of the femur
(P < 0.005). Female patients had significantly reduced bone density at the femoral neck (P < 0.05) only. AED usage was in-
dependently associated with an overall reduction in bone density at femoral sites and contributed to just over 5% of the variance
at the femoral neck. Duration of treatment and type of AED were not independent factors for reduction in BMD. This case-
controlled study supports the hypothesis that long-term AED therapy is an independent risk factor for reduced BMD in epileptic
patients. Adults receiving treatment for epilepsy are at higher risk of osteoporosis and should be offered bone densitometry.
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Osteoporosis is a common bone disease affecting up
to 40% of women and 12% of men1. Fractures result-
ing from reduction in bone mineral density (BMD)
are an important cause of morbidity and mortality;
over one-third of adult women will sustain at least
one osteoporotic fracture. The risk of hip fracture in
white females is doubled by usage of antiepileptic
drugs (AEDs)2. Treatment with older AEDs, such as
phenytoin, carbamazepine and phenobarbital, has been
associated with the production of rickets and osteoma-
lacia3–5 and could, theoretically, contributed to bone
demineralization through secondary hyperparathy-
roidism. However, evidence supporting a deleterious
effect of AEDs on BMD is sparse and conflicting6–12.
The aim of this study was to explore the relationship
between BMD and long-term treatment with enzyme-
and non-enzyme inducing AEDs in epileptic patients.
§ E-mail: Martin.J.Brodie@clinmed.gla.ac.uk1059–1311/99/060339 + 04 $12.00/0MATERIALS AND METHODS
Post-menopausal females and males over 47 years
with treated epilepsy were recruited from the Epilepsy
Clinic at the Western Infirmary in Glasgow. Females
were asked about age at menarche and menopause,
use of hormone replacement therapy, number of preg-
nancies, history of amenorrhoea, hysterectomy and
oophorectomy. Patients with prior or current use of
glucocorticoids, or recipients of other treatments likely
to affect BMD or with a history of any disorder likely
to affect bone, including thyroid disease, were ex-
cluded from entry. Each patient was matched with a
non-epileptic control on no drug therapy for age, sex,
height and weight. Women were also matched as far as
possible for gynaecological and obstetric history, in-
cluding use of hormone replacement therapy. Patients
completed a ‘osteoporosis risk factor’ questionnaire,
giving details of duration of epilepsy, seizure type and
frequency, family history of osteoporosis, fracture his-c© 1999 BEA Trading Ltd
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Factor R2 P value
Weight 21.9% < 0.0001
Weight + age 31.8% < 0.0001 (age)
Weight + age + group 36.8% < 0.0001 (group)
Weight + age + group + sex 40.6% < 0.005 (sex)tory, past medical and drug history, and alcohol in-
take. Details of the protocol were approved by the lo-
cal ethics committee and all patients gave written in-
formed consent to their participation.
All underwent dual-energy X-ray absorptiome-
try (DEXA) bone densitometry at the lumbar spine
and femur (coefficients of variation ∼1%) using a
Hologic QDR-1000TM densitometer (Hologic Inc.,
Waltham, USA). Bone mineral density was measured
and T (the difference in standard deviations between
a given bone density value and peak bone density in
the normal reference population) and Z -scores (age-
adjusted T -score) calculated. Blood was withdrawn at
the same hospital visit for serum calcium and phos-
phate, 25-hydroxyvitamin D, and osteocalcin, which
were assayed using standard commercially available
methodologies. A fasting urine sample was collected
for deoxypyridinoline crosslinks (Pyrilinks-D, Metra
Biosystems, Great Haseley, UK). Comparisons were
made using one-way analysis of variance, regression
analysis, and a paired t-test using MINITAB for Win-
dows statistical package (Version 10.1).
RESULTS
A total of 78 patients (median age 58 years, range 47–
76) with epilepsy (26 idiopathic, 52 partial) were stud-
ied. Overall, 52 and 26 patients (median ages 58 and
57 years, respectively) had only ever been treated with
enzyme-inducing and non-enzyme-inducing AEDs
(Table 1). Duration of AED usage varied between 7–
36 years (mean 23 years) for the enzyme-induced pa-
tients and 5–27 years (mean 10 years) for those tak-
ing non-enzyme-inducing drugs. Forty-eight patients
(17 females (55%) and 18 males (69%) taking enzyme
inducers, and 9 females (53%) and 4 males (44%) tak-
ing non-enzyme inducers) had a history of fractures,
but in only 3 (6%) was this as a consequence of seizure
activity. Thirteen (16%) patients had a family history
of osteoporosis. A total of 45 (54%) patients had been
or were smokers, but only 4 (5%) patients had a his-
tory of alcohol excess.
BMD data compared with controls are summarized
in Table 2. Males with epilepsy had significantly lower
values at the lumber spine (P < 0.01) and femoral
neck (P < 0.005). Females with epilepsy had signifi-
cantly lower BMD at the femoral neck (P < 0.05),
but not at the lumbar spine.
There was no difference in BMD between pa-
tients taking enzyme-inducing and those taking non-
enzyme-inducing AEDs. Both groups had lower BMD
at the femoral neck and lumbar spine than controls.
There were no differences between the epileptic pa-
tients and controls for serum calcium, phosphate and
osteocalcin and urinary deoxypyridinoline crosslinks(data not shown). Mean serum vitamin D levels were
significantly lower in enzyme-induced epileptic pa-
tients than in controls (41 vs. 61 nmol/L, P < 0.0001),
but not in those taking non-enzyme-inducing AEDs
(48 vs. 59 nmol/L).
Factors contributing to the variance in lumbar verte-
bral BMD were identified by best subsets regression.
Of the five identified—age, weight, group (epilepsy
coded as 1, controls coded as O), sex (females coded
as 1, males as O) and smoking (smokers coded as
1, non-smokers as O), weight (P < 0.0001), age
(P = 0.003) and sex (P = 0.005) were shown by
multiple regression analysis to contribute significantly,
accounting for 31.7% of the variance. The regression
equation was:
Lumbar vertebral BMD = 0.941− 0.00439
age + 0.00414 weight − 0.0760 sex.
When BMD was expressed as a Z -score (which cor-
rects for the influence of age), weight was the only
factor that contributed significantly. Similar analyses
were undertaken to assess factors contributing to the
variance in BMD at femoral sites. Stepwise regres-
sion analysis of factors contributing to the variance in
femoral neck bone mineral density are shown below:Group (that is epilepsy or control) accounted for
5.5% of variance in BMD at the greater trochanter and
3.2% at Ward’s triangle. This small but significant con-
tribution was seen whether BMD was expressed abso-
lutely or as a Z -score. The influence of AED treatment
(enzyme-inducers vs. non-inducers) was assessed by
multiple regression analysis. Enzyme-inducing treat-
ment was coded as 1, while non-inducing medication
was coded as O. No significant influence on femoral
BMD was seen with the different subtypes.
DISCUSSION
Osteoporosis is a common condition with major pub-
lic health and economic implications13. Although
both preventable and treatable, the disorder is under-
recognized14. A number of risk factors have been
proposed, including AEDs2. In this study, middle-
aged adult males with epilepsy had a reduction in
BMD at the lumbar spine and femoral neck compared
with matched controls. Post-menopausal females with
epilepsy were also found to have reduced BMD at the
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Table 1: Current antiepileptic drug usage in the study population.
Enzyme-inducers Females Males Non-inducers Females Males
CBZ 10 0 VPA 11 4
PHT 3 3 LTG 2 1
PB 2 2 VGB 0 1
CBZ, PHT 8 4 VPA, LTG 2 0
PB, PHT 4 6 VPA, TPM 1 1
PB, CBZ 1 4 VPA, LTG, TPM 0 1
PB, PHT, CBZ 2 3 VGB, LTG, TPM 0 1
VPA, GBP, LTG 1 0
Total 30 22 17 9
PB = phenobarbital, PHT = phenytoin, CBZ = carbamazepine, VPA = sodium valproate, LTG = lamotrigine, VGB = vigabatrin, TPM =
topiramate, GBP = gabapentin.
Table 2: Mean (SEM) bone density values in patients and controls.
Lumbar spine (± SEM) Femoral neck (± SEM)
Group Subgroup n Bone density T -score Z -score Bone density T -score Z -score
All Control 78 0.94 (0.02) −1.15 (0.17) −0.10 (0.15) 0.77 (0.02) −1.54 (0.14) −0.01 (0.12)
Epilepsy 78 0.90 (0.02) −1.46 (0.16) −0.38 (0.15) 0.71 (0.01)c −2.07 (0.13)c −0.53 (0.12)c
Male Control 31 1.06 (0.03) −0.25 (0.25) −0.28 (0.26) 0.86 (0.02) −1.09 (0.17) −0.32 (0.16)
Epilepsy 31 0.96 (0.03)b −1.18 (0.23)b −0.65 (0.23)b 0.77 (0.02)b −1.91 (0.19)b −0.48 (0.19)b
Female Control 47 0.85 (0.02) −1.75 (0.19) −0.35 (0.16) 0.71 (0.02) −1.83 (0.20) −0.23 (0.16)
Epilepsy 47 0.86 (0.02) −1.64 (0.21) −0.20 (0.20) 0.67 (0.02)a −2.18 (0.17)a −0.55 (0.16)
Inducers Control 52 0.94 (0.03) −1.15 (0.22) −0.06 (0.19) 0.76 (0.02) −1.62 (0.16) −0.04 (0.14)
Epilepsy 52 0.91 (0.02) −1.40 (0.18) −0.28 (0.18) 0.71 (0.02)b −2.09 (0.16)b −0.49 (0.15)a
Non-inducers Control 26 0.93 (0.03) −1.16 (0.29) −0.19 (0.24) 0.78 (0.03) −1.39 (0.28) −0.03 (0.24)
Epilepsy 26 0.88 (0.04) −1.58 (0.31) −0.59 (0.27) 0.70 (0.03)b −2.03 (0.23)a −0.60 (0.21)a
Statistical significance determined by paired t-test: a P < 0.05, b P < 0.01, c P < 0.001.
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